CG Oncology's Investment Narrative Shifts with Positive Cretostimogene Trial Updates and Leadership Moves

CG Oncology has reported positive trial data for cretostimogene, a potential treatment for high-risk non-muscle invasive bladder cancer. The company's expanded access program and growing late-stage trial program could influence its investment narrative, but losses are climbing and regulatory approval is uncertain. The share price is trading above fair value, and there may be further downside.